Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,563 shares of common stock on April 4, 2024, to cover withholding tax liabilities.
Summary
- Richard Paulson, the CEO of Karyopharm Therapeutics Inc., sold 3,563 shares of the company's common stock on April 4, 2024.
- The sale was executed at a price of $1.29 per share.
- This transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021, to cover withholding tax obligations related to the vesting of restricted stock units.
- Following the transaction, Paulson directly owns 1,157,273 shares of Karyopharm Therapeutics Inc.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction (stock sale for tax purposes) by the CEO, which is neither particularly positive nor negative. The existence of a pre-arranged plan mitigates concerns about opportunistic trading.
Industry Context
This is a routine Form 4 filing, reflecting an insider's stock sale to cover tax obligations, which is a common practice.
Key Dates
| Date | Description |
|---|---|
| June 10, 2021 | Date the reporting person adopted a durable automatic sale instruction plan |
| April 04, 2024 | Date of the stock sale transaction |
| April 05, 2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.